Inlyta
Payments companies reported to CMS as associated with Inlyta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Inlyta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Inlyta
These are the largest totals companies reported as associated with Inlyta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Caroline Pratz | Philadelphia, PA | Acute Care (Nurse Practitioner) | $15,111.48 |
| Ulka Vaishampayan | Ann Arbor, MI | Internal Medicine | $12,434.27 |
| Zita Lim | Houston, TX | Physician Assistant | $11,269.04 |
| Moshe Ornstein | Cleveland, OH | Medical Oncology | $9,874.91 |
| Brian Ramnaraign | Gainesville, FL | Hematology & Oncology | $9,563.91 |
| Dale Shepard | Cleveland, OH | Hematology & Oncology | $6,346.60 |
| Ana Paula Harwood | Miami, FL | Nurse Practitioner | $5,900.40 |
| Elizabeth Plimack | Philadelphia, PA | Medical Oncology | $5,510.08 |
| Amit Mehta | Cary, NC | Hematology & Oncology | $5,243.85 |
| Brian Rini | Nashville, TN | Hematology & Oncology | $4,843.68 |
Prescribed Inlyta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.